AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24592967 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioural support intervention consisting of six appointments
Number of subjects: 0
Study 24592967 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural support intervention plus incentives (totalling £40)
Number of subjects: 0
Study 24592967 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 0
Study 21780974 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm AmF/SnF(2) solution (Meridol) - extra-oral application
Number of subjects: 10
Study 21780974 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP crème (Tooth Mousse) - extra-oral application
Number of subjects: 10
Study 21780974 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm AmF/SnF(2) solution (Meridol) - intra-oral application
Number of subjects: 10
Study 21780974 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP crème (Tooth Mousse) - intra-oral application
Number of subjects: 10
Study 21780974 — intervention group
Group type: COMPARATOR
Intervention: Untreated specimens - control
Number of subjects: 10
Study 19853454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-tasking with cognitive tasks during postural sway assessment
Number of subjects: 44
Study 19853454 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tasks (easy or difficult) during postural sway assessment
Number of subjects: 44
Study 17433732 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (intra-arterial, intra-operative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for six hours/day for 4-7 days following surgery)
Number of subjects: 192
Study 17433732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 17433732 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 192
Study 15767221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone use in patients with positive blood cultures for Streptococcus pneumoniae (26.7%)
Number of subjects: 10275
Study 15767221 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolone use in patients with negative blood cultures (34.9%)
Number of subjects: 10275
Study 12409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MR imaging with k space centered at 10-15 seconds
Number of subjects: 100
Study 12409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MR imaging with k space centered at 50 seconds or later
Number of subjects: 100
Study 12409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic imaging with delays of 28-34 seconds or later
Number of subjects: 100
Study 12409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic imaging with k space centered at 10-15 and 50 seconds
Number of subjects: 100
Study 10403597 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQTA 50 U
Number of subjects: 80
Study 10403597 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVRIX 1440 EU
Number of subjects: 80
Study 10403597 — intervention group
Group type: COMPARATOR
Intervention: VAQTA 25 U (3 doses)
Number of subjects: 80
Study 10403597 — intervention group
Group type: COMPARATOR
Intervention: HAVRIX 720 EU (3 doses)
Number of subjects: 80
Study 10403597 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQTA (booster)
Number of subjects: 80
Study 10403597 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVRIX (booster)
Number of subjects: 80
Study 7651666 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic therapy (MgSO4 and terbutaline as first-line agents)
Number of subjects: 0
Study 7651666 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and nifedipine
Number of subjects: 0
Study 2275566 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin, 3 doses
Number of subjects: 130
Study 2275566 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 130
Study 2275566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 2275566 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 130
Study 7371700 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g ingested within 5 min of taking the drugs
Number of subjects: 5
Study 7371700 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 118 g in 5 divided doses given between 10 and 48 hr after ingestion of phenobarbitone
Number of subjects: 5
Study 7371700 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 5
Study 30561719 — intervention group
Group type: COMPARATOR
Intervention: Baxter PD system
Number of subjects: 16575
Study 30561719 — intervention group
Group type: COMPARATOR
Intervention: Fresenius Medical Care PD system
Number of subjects: 16575
Study 30561719 — intervention group
Group type: COMPARATOR
Intervention: Gambro PD system
Number of subjects: 16575
Study 28843186 — intervention group
Group type: COMPARATOR
Intervention: Forward gait retraining (FWG; n=14)
Number of subjects: 29
Study 28843186 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward gait retraining (BWG; n=15)
Number of subjects: 29
Study 25616838 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Safe Sistah program
Number of subjects: 83
Study 25616838 — intervention group
Group type: COMPARATOR
Intervention: Delayed HIV education control condition
Number of subjects: 83
Study 23354666 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with visual feedback
Number of subjects: 0
Study 23354666 — intervention group
Group type: COMPARATOR
Intervention: Trials without visual feedback
Number of subjects: 0
Study 23354666 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical trials
Number of subjects: 0
Study 23354666 — intervention group
Group type: COMPARATOR
Intervention: Motor imagery trials
Number of subjects: 0
Study 21281557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 10
Study 21281557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19056618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (3000 mg/d)
Number of subjects: 121
Study 19056618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 19056618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 121
Study 17697359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran-70 infusion at a dose of 7.5 ml/kg before cardiopulmonary bypass and 12.5 ml/kg after cessation of cardiopulmonary bypass
Number of subjects: 40
Study 17697359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran-70 infusion
Number of subjects: 40
Study 17697359 — intervention group
Group type: COMPARATOR
Intervention: Gelatin infusion (Control)
Number of subjects: 40
Study 15195050 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation excision (CES)
Number of subjects: 89
Study 11226107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microg.kg(‐1).min(‐1) IV (Group A)
Number of subjects: 30
Study 11226107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microg.kg(‐1).min(‐1) IV (Group B)
Number of subjects: 30
Study 11226107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 9745419 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patches (5 mg testosterone over 24 h)
Number of subjects: 41
Study 9745419 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 41
Study 7819847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A 200,000 IU
Number of subjects: 900
Study 7819847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 4043604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 0
Study 4043604 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated, not informed about any problem)
Number of subjects: 0
Study 30480640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phosphate lowering using phosphate binders
Number of subjects: 0
Study 30480640 — intervention group
Group type: COMPARATOR
Intervention: Phosphate binders
Number of subjects: 0
Study 29433578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade (thiazide diuretic, aldosterone-receptor blocker, furosemide, amiloride)
Number of subjects: 80
Study 29433578 — intervention group
Group type: COMPARATOR
Intervention: Dual blockade of the RAAS (ACE inhibitor plus beta-blocker)
Number of subjects: 80
Study 29433578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 26463170 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally consistent diabetes educational program led by a Latino pastor, including weekly reviews of the American Diabetes Association's booklets on diabetes education.
Number of subjects: 0
Study 26463170 — intervention group
Group type: COMPARATOR
Intervention: American Diabetes Association's booklets on diabetes education (control group).
Number of subjects: 0
Study 25062874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 units)
Number of subjects: 159
Study 25062874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat (20 mg)
Number of subjects: 159
Study 25062874 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 159
Study 22399616 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² i.v. d1 q3 weeks (tT)
Number of subjects: 360
Study 22399616 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m² i.v. d1 and d 14, q4 weeks (bT)
Number of subjects: 360
Study 20616541 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (SCT)
Number of subjects: 13
Study 20616541 — intervention group
Group type: COMPARATOR
Intervention: Non-SCT (further intensive post-remission non-myeloablative chemotherapy or no further therapy)
Number of subjects: 13
Study 20616541 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 13
Study 17267715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun safety intervention (provision of wide-brim hats, accessible sunscreen, reminders, and 6 educational sessions)
Number of subjects: 2662
Study 17267715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2662
Study 17607226 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 404
Study 17607226 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 404
Study 15129752 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent nontemporal task
Number of subjects: 0
Study 15129752 — intervention group
Group type: COMPARATOR
Intervention: No concurrent task
Number of subjects: 0
Study 10632230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 107
Study 10632230 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic behavioral family therapy
Number of subjects: 107
Study 10632230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective supportive therapy
Number of subjects: 107
Study 8831331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg + 5 mg.kg‐1.h‐1)
Number of subjects: 30
Study 8831331 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study 8831331 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + 10% Intralipid
Number of subjects: 30
Study 8831331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Midazolam + 10% Intralipid
Number of subjects: 30
Study 1485475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Actovegin 20% (250 ml daily infusion)
Number of subjects: 90
Study 1485475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial Actovegin 20%
Number of subjects: 90
Study 1485475 — intervention group
Group type: COMPARATOR
Intervention: Standardized vascular training
Number of subjects: 90
Study 3934453 — intervention group
Group type: EXPERIMENTAL
Intervention: L-triiodothyronine (LT3) administration
Number of subjects: 7
Study 3934453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LT3 administration)
Number of subjects: 7
Study 3934453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ipodate administration
Number of subjects: 7
Study 30245330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration (20 mg hydrocortisone)
Number of subjects: 43
Study 30245330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28854590 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg, increased to 5 mg if non-responders)
Number of subjects: 159
Study 28854590 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) (50 mg, increased to 100 mg if non-responders)
Number of subjects: 159
Study 28854590 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (after crossover)
Number of subjects: 159
Study 28854590 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (after crossover)
Number of subjects: 159
Study 28854590 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 159
Study 28854590 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC)
Number of subjects: 159
Study 25356528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue dye method
Number of subjects: 60
Study 25356528 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 60
Study 23192417 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intensive attention training program (CR)
Number of subjects: 12
Study 23192417 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (Control)
Number of subjects: 12
Study 22403968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 0
Study 22403968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with sodium bicarbonate
Number of subjects: 0
Study 22403968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine
Number of subjects: 0
Study 22403968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 19701515 — intervention group
Group type: EXPERIMENTAL
Intervention: FRRM with chemical curing
Number of subjects: 100
Study 19701515 — intervention group
Group type: COMPARATOR
Intervention: Resilon alone with chemical curing
Number of subjects: 100
Study 19701515 — intervention group
Group type: EXPERIMENTAL
Intervention: FRRM with QTH standard mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: COMPARATOR
Intervention: Resilon alone with QTH standard mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: EXPERIMENTAL
Intervention: FRRM with QTH ramp mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: COMPARATOR
Intervention: Resilon alone with QTH ramp mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: EXPERIMENTAL
Intervention: FRRM with LED standard mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: COMPARATOR
Intervention: Resilon alone with LED standard mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: EXPERIMENTAL
Intervention: FRRM with LED exponential mode
Number of subjects: 100
Study 19701515 — intervention group
Group type: COMPARATOR
Intervention: Resilon alone with LED exponential mode
Number of subjects: 100
Study 17854590 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 1000 microg once daily
Number of subjects: 36
Study 17854590 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 100 microg once daily
Number of subjects: 36
Study 17854590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White Excel 2 Z 10%
Number of subjects: 105
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White Excel 2 Z 22%
Number of subjects: 105
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence 20%
Number of subjects: 105
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt 10%
Number of subjects: 105
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt 22%
Number of subjects: 105
Study 15130084 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence 10%
Number of subjects: 105
Study 15130084 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent
Number of subjects: 105
Study 11333130 — intervention group
Group type: EXPERIMENTAL
Intervention: DBDT regimen (BCNU 150 mg/m2 i.v. on day 1, cisplatin 25 mg/m2 i.v. daily on days 1 to 3, DTIC 220 mg/m2 i.v. daily on days 1 to 3, tamoxifen 160 mg orally daily for 7 days prior to chemotherapy)
Number of subjects: 60
Study 11333130 — intervention group
Group type: COMPARATOR
Intervention: DTIC alone (1200 mg/m2 i.v. on day 1, repeated every 21 days)
Number of subjects: 60
Study 9129914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral rhizotomies and electrical bladder stimulation with the Finetech‐Brindley stimulator
Number of subjects: 226
Study 8239808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drug regimens
Number of subjects: 927
Study 3120345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 20 mg four times daily
Number of subjects: 44
Study 3120345 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily
Number of subjects: 44
Study 3120345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 44
Study 3120345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30217958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (1000 µg)
Number of subjects: 50
Study 30217958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27012781 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed prasugrel 60-mg loading dose
Number of subjects: 52
Study 27012781 — intervention group
Group type: COMPARATOR
Intervention: Whole prasugrel 60-mg loading dose
Number of subjects: 52
Study 24975869 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment eligibility
Number of subjects: 2274
Study 24975869 — intervention group
Group type: EXPERIMENTAL
Intervention: ARISTOTLE trial eligibility
Number of subjects: 2274
Study 24975869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for ineligibility
Number of subjects: 2274
Study 22619259 — intervention group
Group type: EXPERIMENTAL
Intervention: IV elinogrel (120 mg) plus oral elinogrel (100 mg twice daily)
Number of subjects: 56
Study 22619259 — intervention group
Group type: EXPERIMENTAL
Intervention: IV elinogrel (120 mg) plus oral elinogrel (150 mg twice daily)
Number of subjects: 56
Study 22619259 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and oral elinogrel
Number of subjects: 56
Study 22619259 — intervention group
Group type: EXPERIMENTAL
Intervention: elinoegrel
Number of subjects: 56
Study 22619259 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 56
Study 21092710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 246
Study 21092710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 18584919 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity warfarin anticoagulation
Number of subjects: 0
Study 18584919 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 18584919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist anticoagulants
Number of subjects: 0
Study 16159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood stimulation intervention with weekly home visits by community health aides for one year.
Number of subjects: 139
Study 16159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers receiving > or =40 home visits.
Number of subjects: 139
Study 16159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers receiving 25‐39 home visits.
Number of subjects: 139
Study 16159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers receiving <25 home visits.
Number of subjects: 139
Study 16159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression levels.
Number of subjects: 139
Study 15769072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal tissue transplantation
Number of subjects: 33
Study 15769072 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery (control)
Number of subjects: 33
Study 9864073 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine-case management (IMI-CM)
Number of subjects: 239
Study 9864073 — intervention group
Group type: COMPARATOR
Intervention: pill placebo-case management (Pbo-CM)
Number of subjects: 239
Study 9864073 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy (CBT)
Number of subjects: 239
Study 9864073 — intervention group
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy (IPT)
Number of subjects: 239
Study 8536905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon (Study 1)
Number of subjects: 170
Study 8536905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 1)
Number of subjects: 170
Study 8536905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon (Study 2)
Number of subjects: 170
Study 8536905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 170
Study 8536905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon (both studies)
Number of subjects: 170
Study 2302870 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight
Number of subjects: 20
Study 2302870 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal (i.p.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight
Number of subjects: 20
Study 580863 — intervention group
Group type: EXPERIMENTAL
Intervention: guanadrel sulfate (5 to 20 mg orally every six hours)
Number of subjects: 11
Study 580863 — intervention group
Group type: EXPERIMENTAL
Intervention: guanadrel sulfate
Number of subjects: 11
Study 580863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 29252823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard visit with an 8‐minute video (group A)
Number of subjects: 48